01845nas a2200217   4500008004100000022001400041245010700055210006900162260007600231300001200307490000600319520104600325653002001371653001101391653001101402653001701413100002601430700001901456700002101475856013101496       2011                        eng d  a1860-676800aDifferentiation-inducing ability of sophorolipids of oleic and linoleic acids using a glioma cell line0 aDifferentiationinducing ability of sophorolipids of oleic and li  aCOMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USAbWILEY-BLACKWELLcMAY  a509-5120 v63 a<p>Sophorolipids are biosurfactants produced by non-pathogenic yeasts. They show structural similarity with the membrane components of mammalian cells, i.e., glycosphingolipids and gangliosides, which are involved in processes such as signaling, oncogenesis, and differentiation. Sophorolipids have been reported to induce differentiation in several leukemic cell lines, cell death via apoptosis in a human liver cancer cell line, and necrosis in a pancreatic adenocarcinoma cell line. Here we report, for the first time, the effects of precursor fatty acids and sophorolipids of oleic and linoleic acids in pure acidic and crude forms on LN-229, a glioma cell line. In response to different sophorolipid forms, various morphological changes were observed, such as formation of long thread-like extensions arising from the ends of the cells, cell alignment, cell elongation and bundle formation in a dose-dependent manner. In this study we present the morphological evidence of the potential of sophorolipids as differentiation inducers.</p>10aDifferentiation10aGlioma10aLN-22910aSophorolipid1 aJoshi-Navare, Kasturi1 aShiras, Anjali1 aPrabhune, Asmita  uhttps://library.ncl.res.in/content/differentiation-inducing-ability-sophorolipids-oleic-and-linoleic-acids-using-glioma-cell-002958nas a2200277   4500008004100000022001400041245016700055210006900222260000800291300001100299490000700310520197300317653002502290653002202315653002002337653001102357653002302368653001802391100002602409700002002435700002402455700002102479700003302500700001802533856012902551       2021                        eng d  a2234-943X00aStudy of combinatorial drug synergy of novel acridone derivatives with temozolomide using in-silico and in-vitro methods in the treatment of drug-resistant glioma0 aStudy of combinatorial drug synergy of novel acridone derivative  cMAR  a6258990 v113 a<p>Drug resistance is one of the critical challenges faced in the treatment of Glioma. There are only limited drugs available in the treatment of Glioma and among them Temozolomide (TMZ) has shown some effectiveness in treating Glioma patients, however, the rate of recovery remains poor due to the inability of this drug to act on the drug resistant tumor sub-populations. Hence, in this study three novel Acridone derivative drugs AC2, AC7, and AC26 have been proposed. These molecules when combined with TMZ show major tumor cytotoxicity that is effective in suppressing growth of cancer cells in both drug sensitive and resistant sub-populations of a tumor. In this study a novel mathematical model has been developed to explore the various drug combinations that may be useful for the treatment of resistant Glioma and show that the combinations of TMZ and Acridone derivatives have a synergistic effect. Also, acute toxicity studies of all three acridone derivatives were carried out for 14 days and were found safe for oral administration of 400 mg/kg body weight on albino Wistar rats. Molecular Docking studies of acridone derivatives with P-glycoprotein (P-gp), multiple resistant protein (MRP), and O6-methylguanine-DNA methyltransferase (MGMT) revealed different binding affinities to the transporters contributing to drug resistance. It is observed that while the Acridone derivatives bind with these drug resistance causing proteins, the TMZ can produce its cytotoxicity at a much lower concentration leading to the synergistic effect. The in silico analysis corroborate well with our experimental findings using TMZ resistant (T-98) and drug sensitive (U-87) Glioma cell lines and we propose three novel drug combinations (TMZ with AC2, AC7, and AC26) and dosages that show high synergy, high selectivity and low collateral toxicity for the use in the treatment of drug resistant Glioma, which could be future drugs in the treatment of Glioblastoma.</p>10aacridone derivatives10adrug combinations10adrug resistance10aGlioma10amathematical model10asynergy index1 aChakravarty, Malobika1 aGanguli, Piyali1 aMurahari, Manikanta1 aSarkar, Ram, Rup1 aPeters, Godefridus, Johannes1 aMayur, Y., C.  uhttps://library.ncl.res.in/content/study-combinatorial-drug-synergy-novel-acridone-derivatives-temozolomide-using-silico-and